Académique Documents
Professionnel Documents
Culture Documents
Mulyadi
Pulmonology & Respiratory Medicine Dept.
Faculty of MedicineSyiah Kuala University
Dr. Zainoel Abidin General Hospital
Banda Aceh
Penyakit yg ditandai :
Hambatan aliran udara
Tidak reversibel/reversibel parsial
Progresif
Respons inflamasi abnormal paru
Partikel noxiuos atau gas
1. GOLD 2016
COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease 2. GOLD 2017
Penyebab
Faktor risiko
Host Lingkungan
HOST FACTORS
ANTI OXIDANTS
[ environmental ]
LUNG INFLAMMATION
REPAIR REPAIR
MECHANISM MECHANISM
Bronchiole
Alveoli
Diagnosis of COPD is based
on a history of exposure to risk factors
and the presence of airflow limitation
that is not fully reversible,
with or without the presence of symptoms.
DIAGNOSIS
OF COPD
1 2
SPIROMETRY
A CXRs are seldom diagnostic, it can be useful for excluding other diseases
Spirometry in COPD Diagnosis
0
FEV1 FVC FEV1/ FVC
Normal 4.150 5.200 80 %
1 COPD 2.350 3.900 60 %
2
FEV1
Liter
3
COPD
4 FVC
FEV1
5 Normal
FVC
1 2 3 4 5 6 Seconds
GOLD Workshop Report
Four components of COPD management
4. Manage exacerbations
GOLD major revisions in key areas
Key areas of major revision:
Definition of COPD
ABCD assessment tool
Pharmacological management
Focus on inhaler technique
Management of comorbidities
COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease GOLD 2017
GOLD 2017: Updated COPD definition includes persistent
respiratory symptoms
GOLD 20161 GOLD 20172
Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease
(COPD), a common preventable and (COPD) is a common, preventable and
treatable disease, is characterized by treatable disease that is characterized
persistent airflow limitation that is usually by persistent respiratory symptoms and
progressive and associated with an airflow limitation that is due to airway
enhanced chronic inflammatory and/or alveolar abnormalities usually
response in the airways and the lung to caused by significant exposure to
noxious particles or gases noxious particles or gases
1. GOLD 2016
COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease 2. GOLD 2017
Pendapat tradisional - FEV1 menurun progresifsepanjang waktu
0
25 50 75
Umur (tahun)
Cohort study with 792 working men, 8-year follow-up period, measurement of FEV1 every 6 months
Modified version of the Fletcher and Peto graph showing the decline in FEV1
100
GOLD 1
Pendapat terkini
oleh Tantucci: 40 mL/th
80
FEV1 (% predicted)
Pasien GOLD 2
paling tinggi 47–79 mL/th GOLD 2
penurunan FEV1 50
dibanding pada GOLD 3
56–59 mL/th
stadium
30
akhirCOPD1,2 GOLD 4
<35 mL/th
0
Tahun
Analysis based on randomized control arms of longitudinal studies with a follow-up period ≥3 years
Dashed lines indicate any stage or portion for which consistent information is lacking
Hazard function of the time terhadap eksaserbasi selanjutnya untuk 10 eksaserbasi berat
setelah rawat inap karena PPOK pertamakali.
< 4 bulan Median waktu antara eksaserbasi berat
100 menurun dengan setiap eksaserbasiberat baru ①
Jumlah eksaserbasi berat seanjutnya
①
Risiko terjadi eksaserbasi meningkat ②
60 dan tidak dapat kembali ke risiko baseline ③.
40
5.4 tahun
20 ②+③
0
0 2 4 6 8 10 12
Waktu setelah eksaserbasi berat pertama (tahun)
COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second
GOLD = Global Initiative for Chronic Obstructive Lung Disease GOLD 2017
GOLD : Symptoms and exacerbation risk should be assessed to
determine appropriate treatment
1. Diagnose COPD and determine the severity of airflow limitation (GOLD Grade 1–4) using spirometry
2. Determine GOLD Group (A–D) and subsequent appropriate pharmacological treatment by assessing
symptoms and exacerbation history (including prior hospitalizations)
Exacerbation
history
FEV1
Grade (% pred.) >2 or ≥1
1 ≥80
leading to C D
hospitalization
Post-bronchodilator
2 50–79
FEV1/FVC <0.7
0 or 1
3 30–49 (not leading to A B
hospital admission)
4 <30
• Relieve symptoms
Reduce
• Improve exercise tolerance
symptoms
• Improve health status
COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease GOLD 2017
therapeutic recommendations by GOLD Group
Group C Group D
Consider roflumilast
if FEV1 <50% pred.
LAMA + Consider
and patient has
LABA + ICS chronic bronchitis
macrolide
LABA
Further
exacerbation(s)
Further LAMA + Persistent
exacerbation(s) LABA + ICS symptoms/further
exacerbations
Further
exacerbation(s)
LAMA
LAMA LAMA + LABA LABA + ICS
Group A Group B
Continue, stop or
try alternative class LAMA + LABA
of bronchodilator
Persistent
Evaluate symptoms
effect
A long-acting bronchodilator
A bronchodilator (LABA or LAMA)
FEV1 = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease
ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist GOLD 2017
Group A patients should be offered either a short- or long-acting
bronchodilator
A bronchodilator
Evaluate effect
GOLD = Global initiative for chronic Obstructive Lung Disease GOLD 2017
Group B patients with persistent symptoms should be stepped up
to a LABA/LAMA
LABA or LAMA
Persistent symptoms
LABA + LAMA
More than 50% of GOLD B patients have CAT scores >20 (high symptom burden),2
and therefore should receive LABA/LAMA as initial therapy,
or be stepped up from monotherapy
CAT = COPD Assessment Test; GOLD = Global initiative for chronic Obstructive Lung Disease 1. GOLD 2017; 2. Adelphi Respiratory
LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist Disease Specific Programme 2016
ICS is no longer the preferred choice for patients in GOLD Group C
LAMA
GOLD = Global initiative for chronic Obstructive Lung Disease; ICS = inhaled corticosteroid 1. GOLD 2017
LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist 2.Wedzicha JA, et al. N Engl J Med 2016
Dual bronchodilation is the preferred initial therapy for patients
in Group D
LAMA superior to LABA if Option for initial therapy in
single substance selected Recommended initial therapy patients with possible ACOS
Further
Further exacerbation(s)/
exacerbation(s) persistent symptoms
COPD = chronic obstructive pulmonary disease; GOLD = Global initiative for chronic Obstructive Lung Disease GOLD 2017
Identifying and treating comorbidities is important in patients with
COPD
COPD often coexists with other diseases that may have a significant
impact on health status and prognosis
Cardiovascular disease is a major comorbidity in COPD
Probably the most frequent and most important comorbid disease
Other common comorbidities include skeletal muscle dysfunction,
metabolic syndrome, osteoporosis, depression, anxiety and lung cancer
Comorbidities should be actively sought and treated appropriately
COPD = chronic obstructive pulmonary disease; GOLD = Global initiative for chronic Obstructive Lung Disease GOLD 2017
GOLD 2018 peningkatan pemakaian LAMA/LABA dan
pembatasan ICS pada PPOK
A,B,C,D B,D D
*LABA/ICS may be the first choice in some patients. For example, those with a history and/or findings suggestive of asthma-
COPD overlap.
©2018 Global Initiative for Chronic Obstructive Lung Disease, all rights reserved. Use is by express license from the owner.
This overview is based on the GOLD Report 2018 (chapter 4, management of stable COPD). The new pharmacologic treatment
recommendations provided on this page should not be considered as making a claim of a complete listing of all potential
treatments recommended by GOLD 2018. It should rather be considered as a contribution from Boehringer Ingelheim to help
healthcare professionals to familiarize themselves with the new key recommendations provided by GOLD 2018.
10
1. @2018 Global Initiative forChronic Obstructive Lung Disease, all rights reserved. Use is by
express license from the owner
GOLD 2018
9
Summary: includes major revisions in key areas
Definition of COPD
Refined to place more emphasis on symptoms and comorbidities
Management of comorbidities
Emphasizes the importance of identifying and treating comorbidities
COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease
LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist GOLD 2017
Why doctors are reluctant to treat COPD?